scholarly journals Heart rate response during exercise test and cardiovascular mortality in middle-aged men

2006 ◽  
Vol 27 (5) ◽  
pp. 582-588 ◽  
Author(s):  
Kai P. Savonen ◽  
Timo A. Lakka ◽  
Jari A. Laukkanen ◽  
Pirjo M. Halonen ◽  
Tuomas H. Rauramaa ◽  
...  
2018 ◽  
Vol 62 (6) ◽  
pp. 591-596 ◽  
Author(s):  
Rafael Cavalcante Carvalho ◽  
Patrícia dos Santos Vigário ◽  
Dhiãnah Santini de Oliveira Chachamovitz ◽  
Diego Henrique da Silva Silvestre ◽  
Pablo Rodrigo de Oliveira Silva ◽  
...  

2006 ◽  
Vol 38 (Supplement) ◽  
pp. S434-S435
Author(s):  
Kai Savonen ◽  
Timo Lakka ◽  
Jari Laukkanen ◽  
Tuomas Rauramaa ◽  
Jukka T. Salonen ◽  
...  

1984 ◽  
Vol 66 (6) ◽  
pp. 697-699 ◽  
Author(s):  
D. Fitzgerald ◽  
V. Doyle ◽  
J. G. Kelly ◽  
K. O'Malley

1. The heart rate response to isoprenaline in 11 subjects aged 19–46 years was compared with lymphocyte β-adrenoceptor numbers and lymphocyte cyclic AMP responsiveness. 2. The dose of isoprenaline required to increase heart rate by 25 beats/min (CD25) increased as a function of age (r 0.79; P < 0.01). Lymphocyte receptor numbers also correlated directly with age (r 0.61; P<0.05), but there was no true correlation between CD25 and lymphocyte receptor numbers. 3. Baseline and maximum lymphocyte cyclic AMP concentrations in response to isoprenaline stimulation in vitro were unrelated to age, CD25 or receptor numbers. 4. This study confirms previous findings of a reduced responsiveness with age and a rise in receptor numbers in young and middle-aged adults. However, the decline in the heart response to isoprenaline was unrelated to any measurable change in j3-adrenoceptor concentration or responses, at least in the isolated lymphocyte.


Physiotherapy ◽  
2015 ◽  
Vol 101 ◽  
pp. e819-e820
Author(s):  
E. Lange ◽  
K. Mannerkorpi ◽  
K. Wentz ◽  
Å. Cider

Author(s):  
Yazan Assaf ◽  
Ahmad Barout ◽  
Ahmad Alhamid ◽  
Ahmad Al-Mouakeh ◽  
Maria Irene Barillas-Lara ◽  
...  

We sought to update norms for peak systolic blood pressure (SBP) on the graded exercise test and examine its prognostic value in patients without baseline cardiovascular disease. Mayo graded exercise test data (1993–2010) were reviewed for nonimaging tests using Bruce protocol, selecting Minnesota residents 30 to 79 years without baseline cardiovascular disease. We formed a pure cohort of patients without factors significantly affecting peak SBP to determine peak SBP percentile norms by age and sex. Then we divided the full cohort of patients into 5 groups based on peak SBP percentiles: low (<10th), borderline low (10th–25th), referent (25th–75th), borderline high (75th–90th), and high (>90th). The relationship between peak SBP and mortality was tested using Cox regression adjusting for age, sex, and comorbidities affecting peak SBP or mortality. We identified 20 760 eligible patients with 7313 females (35%) and mean age 51.5±10.7 years. Our pure cohort included 7810 patients. Over 12.5±5.0 years follow-up, there were 1582 deaths, including 541 cardiovascular deaths. In the fully adjusted model, low-peak SBP was associated with increased total mortality (heart rate, 1.41 [1.19–1.66], P <0.0001) and cardiovascular mortality (heart rate, 1.54 [1.16–2.03], P =0.001), while borderline low-peak SBP was associated with increased cardiovascular mortality only (heart rate, 1.36 [1.02–1.81], P =0.027). High peak SBP was associated with increased total mortality only in the age-sex adjusted model (heart rate, 1.18 [1.02–1.36], P =0.026), not after full adjustment. We conclude that low exercise peak SBP is an independent predictor of higher total and cardiovascular mortality.


2019 ◽  
Vol 7 ◽  
Author(s):  
Fabian von Scheidt ◽  
Stephanie Meier ◽  
Johannes Krämer ◽  
Anita Apitz ◽  
Jannos Siaplaouras ◽  
...  

1957 ◽  
Author(s):  
Philip J. Bersh ◽  
Joseph M. Notterman ◽  
William N. Schoenfeld

Sign in / Sign up

Export Citation Format

Share Document